Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDE849 in DLL3-expressing tumors including small cell lung cancer
2025-523438-24-00Phase 2Authorised
- Sponsor
- IDEAYA Biosciences
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of SHR-4849 in small cell lung cancer (SCLC), neuroendocrine carcinoma (NEC), Merkel cell carcinoma (MCC) and 1 more (8 arms), sponsored by IDEAYA Biosciences. Primary endpoints: Dose-limiting toxicity incidence, Adverse events and serious adverse events and 2 more. Planned start Jul 2026; status: authorised.
02
Drugs
SHR-4849
03
Conditions
small cell lung cancer (SCLC)neuroendocrine carcinoma (NEC)Merkel cell carcinoma (MCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2025-523438-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523438-24-00.